RCS - Oxford Biomedica PLC - Launch of viral vector fast-track offering

Oxford BioMedicaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260413:nRSM1475Aa&default-theme=true

RNS Number : 1475A  Oxford Biomedica PLC  13 April 2026

 

 

OXB launches fast-track offering for AAV and lentiviral vector platforms,
accelerating viral vector development and manufacture

-     New expedited service line designed for biotechs with timeline
constraints, launched in response to client demand

-     Can accelerate timeline to GMP manufacturing by up to nine months,
driven by key innovations and efficiencies across upstream and downstream
processes

 

Oxford, UK - 13 April 2026: OXB (LSE: OXB), a global quality and
innovation-led cell and gene therapy CDMO, today announces the launch of its
new fast-track development and manufacturing offering, providing an expedited
route to GMP manufacture for clients utilising lentiviral (LV) and
adeno-associated viral (AAV) vectors.

Launched in response to growing client demand, OXB's fast-track offering
provides a cost-effective, accelerated option for  biotechs with eligible
programmes, using the Company's proprietary inAAVate™ and LentiVector™
platforms. These faster timelines will help OXB's clients maintain a
competitive edge in the market, enabling them to achieve clinical and
regulatory milestones earlier, ultimately leading to faster access to
transformative treatments for patients.

OXB's fast-track programme for AAV vectors can accelerate the pathway to GMP
manufacture from an industry standard ~15 months to as little as seven months.
Particularly suitable for wild type AAVs, this has been achieved through the
use of a high-performance plug-and-play platform, reducing the need for a
number of development steps while achieving high titers and more consistent
performance at relevant development scales, and through OXB's in-house
expertise for accelerated analytical development and qualification.

For the manufacture of lentiviral vectors, OXB's fast-track offering
accelerates an industry-standard 12-18 month timeline to as little as nine
months, through the use of platform datasets and advanced analytics, and
proceeding directly from scale-down models into GMP manufacturing. Additional
efficiencies are achieved through the integration of vector design,
production, purification, and fill-finish, shortening timelines.

Through the launch of this offering specifically designed for innovative
clients where time or financing is limited, OXB is extending the global reach
of its inAAVate™ and LentiVector™ platforms, reinforcing OXB's position as
a trusted provider of viral vector development and manufacturing services.

Dr Sébastien Ribault, Chief Business Officer of OXB, said: "For emerging cell
and gene therapy companies, viral vector development and manufacture
represents a frequent bottleneck to clinical readiness, and issues can delay
critical clinical milestones. The launch of our fast-track offering will make
our proprietary inAAVate™ and LentiVector™ platforms accessible to a wider
range of clients who are looking for an expedited route to GMP manufacture and
the clinic, cutting industry standard development timelines by up to 50%."

 

-Ends-

 

Enquiries:

 

OXB:

Sebastien Ribault, Chief Business Officer - T: +44 (0) 1865 783 000 / E:
partnering@oxb.com (mailto:partnering@oxb.com)

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Sarah Elton-Farr / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

OXB offers a vast number of technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the TetraVecta™
system), a dual-plasmid system for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It
has development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com
(http://www.oxb.com) and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAAKBBPOBKDAQD



            Copyright 2019 Regulatory News Service, all rights reserved